End-of-day quote
Australian S.E.
|
5-day change
|
1st Jan Change
|
- AUD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: June |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
27.65
|
4.147
|
2.765
|
Enterprise Value (EV)
1 |
27.63
|
5.91
|
5.042
|
P/E ratio
|
-7.08
x
|
-0.53
x
|
-1.82
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
305,404,639
x
|
112,395,528
x
|
EV / Revenue
|
-
|
435,205,817
x
|
204,957,276
x
|
EV / EBITDA
|
-
|
-
|
-
|
EV / FCF
|
-11,167,216
x
|
-1,419,925
x
|
33,514,906
x
|
FCF Yield
|
-0%
|
-0%
|
0%
|
Price to Book
|
3.31
x
|
5.63
x
|
-4.76
x
|
Nbr of stocks (in thousands)
|
138,247
|
138,247
|
138,247
|
Reference price
2 |
0.2000
|
0.0300
|
0.0200
|
Announcement Date
|
07/09/21
|
10/08/22
|
06/09/23
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
0.0136
|
0.0246
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.5814
|
-1.418
|
-3.244
|
-1.541
|
-1.204
|
Operating Margin
|
-
|
-
|
-
|
-11,349.04%
|
-4,892.53%
|
Earnings before Tax (EBT)
1 |
2.75
|
-1.418
|
-3.904
|
-1.663
|
-1.522
|
Net income
1 |
2.75
|
-1.418
|
-3.904
|
-7.873
|
-1.522
|
Net margin
|
-
|
-
|
-
|
-57,977.61%
|
-6,186.86%
|
EPS
2 |
0.0393
|
-0.0199
|
-0.0282
|
-0.0570
|
-0.0110
|
Free Cash Flow
|
-
|
0.3221
|
-2.474
|
-4.162
|
0.1504
|
FCF margin
|
-
|
-
|
-
|
-30,649.93%
|
611.54%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/02/20
|
26/05/21
|
07/09/21
|
10/08/22
|
06/09/23
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.23
|
2.5
|
-
|
1.76
|
2.28
|
Net Cash position
1 |
-
|
-
|
0.02
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
0.32
|
-2.47
|
-4.16
|
0.15
|
ROE (net income / shareholders' equity)
|
-
|
-54.5%
|
-56.6%
|
-36.5%
|
-1,946%
|
ROA (Net income/ Total Assets)
|
-
|
-17.9%
|
-21%
|
-14.6%
|
-21.4%
|
Assets
1 |
-
|
7.935
|
18.62
|
53.81
|
7.122
|
Book Value Per Share
2 |
-0
|
0.0500
|
0.0600
|
0.0100
|
-0
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/02/20
|
26/05/21
|
07/09/21
|
10/08/22
|
06/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +15.58% | 122B | | +16.60% | 113B | | +17.55% | 26.22B | | -24.33% | 19.01B | | -19.14% | 15.71B | | -17.95% | 15.22B | | -46.81% | 14.72B | | +58.78% | 14.58B | | +4.91% | 13.84B |
Bio Therapeutic Drugs
|